Abstract
Schlafen-11 (SLFN-11) was recently identified as a predictive marker of platinum-based drugs. In Japan, neoadjuvant chemotherapy, consists of 5-fluorouracil and cisplatin (NAC-FP), followed by surgery is the standard therapy for patients (pts) with resectable esophageal squamous cell carcinoma (ESCC). However, the correlation between SLFN-11 expression level and prognosis in ESCC pts treated with NAC-FP is unclear.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
